![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, July 13, 2016 8:33:39 AM
JERSEY CITY, N.J., July 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the Company has entered into an Asset Purchase agreement with UK-based Cypralis Limited, a life sciences company focused on the discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases (PPIases), for the sale of its cyclophilin inhibitor assets. Cypralis will also acquire all patents, patent applications and know-how related to the acquired portfolio. Financial terms of the agreement were not disclosed.
In connection with the Asset Purchase agreement, SCYNEXIS is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. SCYNEXIS retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized.
"We are pleased to entrust these non-core assets to Cypralis, a clear leader in the field of PPIase-targeted therapeutics," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "This transaction will allow us to focus our efforts and resources on our lead program, SCY-078, for the treatment of serious and life-threatening fungal infections. Additionally, as part of the agreement, we have retained the rights to certain compounds that strategically fit within our focus areas of anti-infectives, dermatology and ophthalmology and have the potential to broaden our development pipeline."
About SCY-078
SCY-078 is an oral glucan synthase inhibitor in Phase 2 development for the treatment of fungal infections caused by Candida and Aspergillus species. SCY-078 is a semi-synthetic derivative of the natural product enfumafungin—a structurally distinct class of glucan synthase inhibitors. SCY-078 combines the well-established activity of glucan synthase inhibitors with the flexibility of use of azole with both oral and IV formulations. By belonging to a chemical class distinct from other antifungals, SCY-078 has shown in vitro activity against multi-drug resistant pathogens, including azole and echinocandin resistant strains. SCY-078 is currently in Phase 2 development with the oral formulations in two indications: invasive candidiasis and vulvovaginal candidiasis. SCY-078 has received both Fast Track and QIDP designations from the FDA for the oral and intravenous (IV) formulations for the indications of invasive candidiasis (including candidemia) and invasive aspergillosis.
About SCYNEXIS, Inc.
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.SCYNEXIS.com.
Recent SCYX News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:07:47 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/20/2024 12:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:01:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:48:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:09:53 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:41:39 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:32:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:03:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:01:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:01:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 02:53:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:01:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/28/2023 09:05:54 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/28/2023 09:05:51 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/28/2023 05:15:14 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2023 10:09:33 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2023 09:45:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:01:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 01:15:16 PM
- SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance • GlobeNewswire Inc. • 09/28/2023 12:31:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 12:32:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:01:54 PM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM